Bavarian Nordic — Februar 2019
-
News | Bavarian Nordic
Bavarian Nordic - a pioneering force in vaccines – expanding our reach and impact through life-changing solutions
(www.bavarian-nordic.com)
-
MVA-BN HPV is a new vaccine candidate, designed for Janssen as part of the development of a prime-boost vaccine regimen with Janssen’s AdVac technology. The prime-boost vaccine is targeting HPV and represents a novel approach for early treatment and interception of HPV-induced cancers The long-term goal is to develop a vaccine to treat chronic HPV infections as well as prevent precancerous stages of HPV-induced cancer.
-
With over 300 million estimated infections among men and women annually, HPV (human papillomavirus) is the most prevalent sexually transmitted disease in the world.
HPV is the primary cause of cervical cancer and certain types of head and neck cancer, in addition to a number of more rare cancers. Although vaccines have become available to protect against various high-risk HPV subtypes that can cause cancer, there is an unmet need for a therapeutic approach for chronic infections that may lead
-
-
-
Opstart i H2 2018: http://www.bavarian-nordic.com/media/273834/2018-q3-en.pdf
-
I øvrigt tror jeg vi vil se et fint nyheds-/forsøgsdata-momentum bygge op i løbet af 19, så er meget positiv på BAVA lige nu. De har en virusbaseret leveringsteknologi, der virkelig kan noget særligt. Flere meget interessante stoffer. Om godt 1 år har de osse en stor og hyper moderne fabrikationsfacilitet (betalt af den amerikanske regering... ref. Trump, der ville have Mexico til at betale for muren. Hi hi...), som formentlig ikke findes mage mange steder.
-
Ingen tvivl om, at de har de-risket nyhedsflowet og pipelinen med deres aflysning af RSV human challenge og aflysning af de ekstra selvfinansierede CV301 projekter. Det kommer til at ligne et nyhedsflow med neutrale (opstart af X forsøg) og positive nyheder (FDA godkendelse af Imvamune) henover året med kun meget få relativt begrænsede negative triggere (såsom dårlige brachyury/CV301 resultater). Den store trigger er evt. partnerskab på RSV, som p.t. er et område.....
-
-
Biotekchef på vej til udlandet stopper i dansk bestyrelsesjob
Britt Meelby Jensen, der kun har få dage tilbage som topchef i Zealand Pharma, forlader nu også diagnostikselskabet Bioporto, hvor hun siden foråret sidste år har siddet i bestyrelsen sammen med blandt andre Symphogen-stifteren Kirsten Drejer.
Biotekchef på vej til udlandet stopper i dansk bestyrelsesjob
Britt Meelby Jensen, der kun har få dage tilbage som topchef i Zealand Pharma, forlader nu også diagnostikselskabet Bioporto, hvor hun siden foråret sidste år har siddet i bestyrelsen sammen med blandt andre Symphogen-stifteren Kirsten Drejer.
Finans (finans.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind